Get started
Author

Venkata Preetam Sandeep Kaduluri

Integrated domestic violence and reproductive health interventions in India: a systematic review
2024 · Bushra Sabri, Serena Sloka Mani, et al. · Reproductive Health · 11
A Retrospective Analysis of Intensive Chemotherapy Vs. Venetoclax/Hypomethylating Agents for Patients Aged 60-75 with Favorable-Risk, NPM1-Mutated AML
2024 · Andrew Zale, Alexander J. Ambinder, et al. · Blood · 2
PDF
Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques
2025 · John Claiborne, Venkata Preetam Sandeep Kaduluri, et al. · Blood · 1
PDF
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
2025 · Andrew D Zale, Venkata Preetam Sandeep Kaduluri, et al. · Blood Neoplasia · 1
Metronomic decitabine with venetoclax offers a patient-centered frontline therapeutic approach for TP53-mutated complex-karyotype myeloid neoplasms
2026 · Laura Frances Walsh, Royce P. Lee, et al. · Haematologica
PDF
72455 Cutaneous Toxicity Patterns and Clinical Outcomes in Patients Treated with Pegylated Liposomal Doxorubicin (PLD): A Multi-Cancer Cohort Study
2026 · Toan Bui, Nazila Shafagati, et al. · Journal of the American Academy of Dermatology
Prognostic Significance of Absolute Lymphocyte Count (ALC) and Lymphodepletion (LD) Regimen in Chimeric Antigen Receptor T-cell Therapy (CAR T)
2026 · Andrew Ly, Vidya Babu, et al. · Transplantation and Cellular Therapy
Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies
2025 · Zachary Hing, Colin Thomas, et al. · Blood
PDF
Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients
2025 · Yun Kyoung Tiger, Charlotte Zuber, et al. · Blood
PDF
Outcomes of adolescent and young adult patients with AML treated on adult versus pediatric protocols
2025 · Ira Kraft, Venkata Preetam Sandeep Kaduluri, et al. · Blood
PDF
Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis
2025 · Omar Elghawy, Nishwant Swami, et al. · Blood
Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms
2025 · Laura Walsh, Venkata Preetam Sandeep Kaduluri, et al. · Blood
PDF
Characterizing Cutaneous Toxicity from Pegylated Liposomal Doxorubicin in MF/SS, Kaposi Sarcoma, and Leiomyosarcoma: A 15-Year Single-Center Review
2025 · Toan Bui, Nazila Shafagati, et al. · European Journal of Cancer
Characterizing cutaneous toxicity from doxorubicin.
2025 · Nazila Shafagati, Cole Harris Sterling, et al. · Journal of Clinical Oncology
PDF
A Retrospective Cohort Analysis of Minimal Residual Disease (MRD) across Therapy in FLT3 Acute Myeloid Leukemia (AML)
2024 · Arshia Arora, Hua-Ling Tsai, et al. · Blood
PDF
Works count: 15
Citation count: 15
H-index: 2
I10-index: 1
Year
Topic
Type